NCT03760081View on ClinicalTrials.gov

A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

March 19, 2019

Primary Completion Date

October 16, 2020

Study Completion Date

October 16, 2020

Conditions
Incurable Platinum Refractory Germ Cell TumorsTumors
Interventions
DRUG

ASP1650

Participants received ASP1650 dose level 1 or dose level 2 as intravenous infusion, Q2W starting on C1D1 for up to a maximum of 12 cycles or until study discontinuation criterion was met, whichever occurred earlier. Duration of each treatment cycle was 14 days.

Trial Locations (3)

10065

Memorial Sloan-Kettering Cancer Center, New York

19104

Abramson Cancer Center University of Pennsylvania, Philadelphia

46202

Indiana University Simon Cancer Center, Indianapolis

All Listed Sponsors
lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT03760081 - A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors | Biotech Hunter | Biotech Hunter